Inmune Bio (INMB) Enterprise Value (2017 - 2025)
Historic Enterprise Value for Inmune Bio (INMB) over the last 9 years, with Q3 2025 value amounting to -$27.7 million.
- Inmune Bio's Enterprise Value rose 1734.02% to -$27.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.7 million, marking a year-over-year increase of 1734.02%. This contributed to the annual value of -$20.9 million for FY2024, which is 4163.69% up from last year.
- According to the latest figures from Q3 2025, Inmune Bio's Enterprise Value is -$27.7 million, which was up 1734.02% from -$33.4 million recorded in Q2 2025.
- Over the past 5 years, Inmune Bio's Enterprise Value peaked at -$19.3 million during Q1 2025, and registered a low of -$84.5 million during Q3 2021.
- Its 5-year average for Enterprise Value is -$44.7 million, with a median of -$41.8 million in 2023.
- In the last 5 years, Inmune Bio's Enterprise Value plummeted by 72059.8% in 2021 and then soared by 4901.87% in 2024.
- Quarter analysis of 5 years shows Inmune Bio's Enterprise Value stood at -$74.8 million in 2021, then soared by 30.29% to -$52.2 million in 2022, then skyrocketed by 31.26% to -$35.8 million in 2023, then skyrocketed by 41.64% to -$20.9 million in 2024, then crashed by 32.56% to -$27.7 million in 2025.
- Its Enterprise Value was -$27.7 million in Q3 2025, compared to -$33.4 million in Q2 2025 and -$19.3 million in Q1 2025.